Quick Take
Guardant Health (GH) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.
The firm provides genomic cancer testing services from a single blood draw.
GH is growing at an accelerating rate, has ample resources and continues to develop new, non-invasive cancer screening tests.
When we learn more details about the IPO, I’ll provide an update.
Company & Technology
Redwood City, California-based Guardant Health was founded in 2012 to improve the lives of cancer patients with comprehensive screening and early detection by